Open AccessImmunotherapy in the treatment of lymphoma
Author(s) -
Lazar Popović,
Gorana Matovina-Brko,
Maja Popović,
M. Popović,
Ana Cvetanović,
Ivan Nikolić,
Biljana Kukić,
Danijela Petrović
Publication year - 2021
Publication title -
world journal of stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 18
ISSN - 1948-0210
DOI - 10.4252/wjsc.v13.i6.503
Subject(s) - medicine , lymphoma , immunotherapy , refractory (planetary science) , disease , salvage therapy , chemotherapy , oncology , transplantation , intensive care medicine , cancer , physics , astrobiology
Relapsed or refractory non-Hodgkin's lymphomas, especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat diseases. Patients who do not respond to initial therapy or experience relapse are treated with salvage regimens, and if eligible for aggressive therapy, treatment is continued with high-dose chemotherapy and autologous stem cell transplantation. Current therapy options can cure substantial numbers of patients, however for some it is still an uncurable disease. Numerous new drugs and cell therapies are being investigated for the treatment of relapsed or refractory lymphomas. Different types of immunotherapy options have shown promising results, and some have already become the standard of care. Here, we review immunotherapy options for the treatment of lymphoma and discuss the results, positions, practical aspects, and future directions of different drugs and cellular therapies for the treatment of this disease.